The present invention generally relates to compounds and pharmaceutical compositions containing the compounds. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
本发明通常涉及化合物和含有这些化合物的药物组合物。更具体地说,本发明的化合物是六
氢吲哚并
环己氮化
吲哚和八
氢吲哚并
环己氮化
吲哚化合物。这些化合物是
血清素受体(5-HT)
配体,可用于治疗希望调节
血清素受体(5-HT)活性的疾病、障碍和病况(例如焦虑、抑郁和肥胖症)。